In the adjuvant setting, targeted therapies for melanoma substantially reduced the risk of relapse by 53% compared to placebo, leading to the approval of BRAF plus MEK inhibitors as a treatment option for stage III melanoma [6]. The gene discussed is MAP2K7; the disease is melanoma.